Back to search

Article

Activation of ERBB4 in glioblastoma can contribute to increased tumorigenicity and influence therapeutic response

2018-06-12

Abstract excerpt

Glioblastoma (GBM) is often resistant to conventional and targeted therapeutics. ERBB4 is expressed throughout normal brain and is an oncogene in several pediatric brain cancers; therefore, we investigated ERBB4 as a prognostic marker and therapeutic target in GBM. Using RT-qPCR, we quantified mRNA encoding total ERBB4 and known ERBB4 variants in GBM and non-neoplastic normal brain (NNB) samples. Using immunohisto...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
b621f3b0-4a07-5eed-8aa6-a88eaf87518f
DOI
10.20944/preprints201806.0197.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Activation of ERBB4 in glioblastoma can contribute to increased tumorigenicity and influence therapeutic responseDOI 10.20944/preprints201806.0197.v1
Select a neighboring publication to make it the new centre.